Of these studies, which involved p16INK4A and p14ARF gene promoter methylation, nine studies evaluated the association between p16INK4A promoter methylation and RCC risk, five studies assessed the correlation between p14ARF promoter methylation and RCC risk, ten studies evaluated the relation between p16INK4A promoter methylation and clinicopathological features, and four studies evaluated the relation between p14ARF promoter methylation and clinicopathological features. The gene discussed is CDKN2A; the disease is renal cell carcinoma.